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OBJECTIVE — The aim of this study was to assess the incremental value of dobutamine stress
echocardiography (DSE) for the risk stratification of diabetic patients who are unable to perform
an adequate exercise stress test. Exercise capacity is frequently impaired in patients with diabe-
tes. The role of pharmacologic stress echocardiography in the risk stratification of diabetic
patients has not been well defined.
RESEARCH DESIGN AND METHODS — We studied 396 diabetic patients (mean age
61  11 years, 252 men [64%]) with limited exercise capacity who underwent DSE for evalu-
ation of known or suspected coronary artery disease (CAD). End points were hard cardiac events
(cardiac death and nonfatal myocardial infarction) and all causes of mortality.
RESULTS — During a median follow-up of 3 years, 97 patients (24%) died (55 cardiac
deaths), and 27 patients had nonfatal myocardial infarction. In an incremental multivariate
analysis model, clinical predictors of hard cardiac events were history of congestive heart failure,
previous myocardial infarction, hypercholesterolemia, and ejection fraction at rest. The percent-
age of ischemic segments was incremental to the clinical model in the prediction of hard cardiac
events (2  37 vs. 18, P  0.05). Clinical predictors of all causes of mortality were history of
congestive heart failure, age, hypercholesterolemia, and ejection fraction at rest. Wall motion
score index at peak stress was incremental to the clinical model in the prediction of mortality
(2  52 vs. 43, P  0.05).
CONCLUSIONS — DSE provides incremental data for the prediction of mortality and hard
cardiac events in patients with diabetes who are unable to perform an adequate exercise stress
test.
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D iabetes is a major risk factor for cor-onary artery disease (CAD) and itscomplications (1–7). Identification
of diabetic patients at a high risk of death
and myocardial infarction is an essential
step for planning the appropriate man-
agement strategy. Exercise stress testing is
the most widely used method for evalua-
tion of CAD (8–10). However, exercise
capacity is frequently impaired in diabetic
patients, particularly because of the
higher prevalence of peripheral neuropa-
thy and vascular disease in this popula-
t ion (11–14). Dobutamine stress
echocardiography (DSE) has been re-
ported as a safe and feasible method for
evaluation of CAD in diabetic patients
with limited exercise capacity (15,16).
However, data regarding the incremental
value of the technique in the risk stratifi-
cation of diabetic patients are scarce (2).
Additionally, currently there is no out-
come data to support the role of stress
echocardiography in the prediction of all
causes of mortality in diabetic patients.
The aim of this study was to assess the
incremental value of DSE in the predic-
tion of death and hard cardiac events in
diabetic patients after adjustment for clin-
ical data.
RESEARCH DESIGN AND
METHODS
Patients
The study included 408 patients with di-
abetes who were unable to perform an ad-
equate exercise test, who underwent DSE
at the Thoraxcenter (Rotterdam, the
Netherlands) between January 1994 and
January 2001. Diabetes was defined in the
presence of a fasting blood glucose140
mg/dl or requirement for insulin or oral
hypoglycemic agents. Seven patients were
excluded because of inadequate echocar-
diographic images and five patients were
lost to follow-up. The final population of
the study consisted of 396 patients. Hy-
percholesterolemia was defined as total
cholesterol 200 mg/dl or use of a cho-
lesterol-lowering agent. Hypertension
was defined as systolic blood pressure
140 mmHg, diastolic blood pressure
90 mmHg, or use of antihypertensive
medication. Heart failure was defined ac-
cording to the New York Heart Associa-
tion classification. Patients’ clinical
characteristics are presented in Table 1.
The local medical ethics committee ap-
proved the study protocol. Patients gave
an informed consent to undergo the
study.
DSE protocol
Left ventricular (LV) ejection fraction at
rest was assessed using the modified bi-
plane Simpson rule (17). After baseline
echocardiography, dobutamine was in-
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fused at a starting dose of 5 g/kg per
minute for 3 min, followed by 10 g 
kg1  min1 for 3 min (low-dose stage).
The dobutamine dose was increased by
10 g  kg1  min1 every 3 min, up to a
maximum dose of 40 g  kg1  min1.
Atropine (up to 1 mg) was administered
intravenously at the end of the last stage if
the target heart rate was not achieved.
End points of the test were an achieve-
ment of the target heart rate (85% of the
maximal heart rate predicted for age), the
maximal dose of dobutamine and atro-
pine, 2 mV downsloping ST-segment
depression measured 80 ms from the J
point compared with baseline, hyperten-
sion (blood pressure 240/120 mmHg),
a decrease in systolic blood pressure of
40 mmHg, and significant arrhythmias.
Echocardiographic imaging and
interpretation
Imaging was acquired at rest and contin-
uously during the test and recovery. Im-
ages were recorded on videotapes and, in
addition, the baseline, low-dose, peak-
stress, and recovery images were recorded
in a quad-screen format.
The interpretation of images was per-
formed by two independent observers
blinded to the patients’ clinical data. In
case of disagreement, a majority decision
was achieved by a third observer. In our
laboratory, the inter- and intraobserver
agreement for DSE assessment are 92 and
94%, respectively (18). A 16-segment
model was used for segmental analysis of
LV function (17). Wall motion score in-
dex was determined at rest and peak
stress as the sum of the segmental scores
of the 16 segments divided by 16. Each
segment was scored using a 5-point scale
as follows: 1  normal, 2  mild hypo-
kinesis, 3 severe hypokinesis, 4 aki-
nesis, 5  dyskinesis. Ischemia was
defined as new or worsened wall motion
abnormalities during stress, which was
indicated by an increase of wall motion
score1 grade in1 segment (19). Isch-
emia was not considered to be present
when akinetic segments at rest became
dyskinetic during stress (20). DSE results
were defined as abnormal if there was
ischemia during stress or fixed wall mo-
tion abnormalities (19).
Follow-up
Follow-up was obtained by mailed ques-
tionnaires and scripted telephone inter-
views. Events were verified by contacting
the patients’ primary physician and re-
viewing medical records and death certif-
icates. The end points considered were all
causes of mortality and hard cardiac
events (defined as nonfatal myocardial in-
farction and cardiac death). Sudden un-
expected death occurring without
another explanation was included as car-
diac death. Myocardial infarction was de-
fined according to usual clinical,
electrocardiographic, and enzymatic
criteria.
Statistical analysis
Continuous variables were presented as
mean  SD. Comparisons between
groups were based on the Wilcoxon’s
rank-sum test. Categorical variables were
summarized as percentages and group
comparisons were based on the 2 test.
Survival free of the end point of interest
was estimated by the Kaplan-Meier
method. Univariable and multivariable
association of clinical and stress echocar-
diographic parameters with the end
points of interest were assessed in the Cox
proportional hazards framework. Vari-
ables were selected in a stepwise forward
selection manner with entry and retention
set at a significance level of 0.05. The re-
sults of these analyses were summarized
as hazard ratios with corresponding 95%
CIs. The incremental value of DSE infor-
mation over clinical data was assessed in
two modeling steps. The first step con-
sisted of fitting a multivariable model of
only clinical data. Variables selected from
the first step were then used as baseline
risk factors, and dobutamine echocardio-
graphic variables were added in a step-
wise forward selection manner.
RESULTS — Clinical features are pre-
sented in Table 1. Dobutamine-atropine
induced a significant increase of heart rate
(77 13 at rest to 132 16 beats/min at
peak dose, P 0.0001), whereas systolic
blood pressure did not increase (137 
27 mmHg at rest and 136 32 mmHg at
peak stress). Atropine was administered
in 179 patients (45%). Angina occurred
in 89 patients (22%), and ST-segment de-
pression occurred in 61 patients (15%).
Reasons for termination of the test were
achievement of target heart rate in 320
patients (81%), angina in 42 patients
(11%), ST-segment depression in 22 pa-
tients (5%), hypotension in 7 patients
(2%), and ventricular arrhythmia in 5 pa-
tients (1%).
Resting wall motion abnormalities
were detected in 309 patients (78%).
Ischemia was detected in 144 patients
(36%), and 129 of these patients had rest-
ing wall motion abnormalities as well.
Among the 129 patients with resting and
dobutamine-induced wall motion abnor-
malities, ischemia occurred in the vascu-
lar territory with resting wall motion
abnormalities in 116 patients, whereas
the remaining 13 patients had ischemia in
vascular regions with normal resting wall
motion in the related myocardial seg-
ments. DSE was considered abnormal
(rest- and/or stress-induced wall motion
abnormalities) in 324 patients (82%).
Outcome
During a median follow-up of 3 years
(maximum 7 years), 97 patients (24%)
died (55 cardiac deaths), 27 patients had
nonfatal myocardial infarction (82 hard
cardiac events), and 59 patients (15%)
underwent myocardial revascularization.
Table 1—Clinical characteristics of the study
population
Characteristics (N  396) n %
Sex (male) 252 64
Age (years) 61  11
Previous myocardial infarction 205 52
Previous myocardial
revascularization
191 48
History of typical angina
pectoris
140 35
History of heart failure (class
I–II)
40 10
History of heart failure (class
III–IV)
44 11
Hypertension 183 46
Hypercholesterolemia 145 37
Smoking 123 31
-blockers 144 36
Calcium channels blockers 151 38
ACE inhibitors 192 48
Aspirin 277 70
Statins 138 35
Diabetic nephropaty 32 8
Diabetes type 2 344 87
Diabetes type 1 52 13
Reason for referral
Evaluation of chest pain 234 59
Preoperative assessment 4 1
Evaluation of risk factors 141 36
Functional assessment after
myocardial infarction
17 4
ACE, angiotensin-converting enzyme.
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Fifteen patients (4%) underwent early re-
vascularization (within 3 months after
DSE), and 44 patients (11%) underwent
late revascularization (3 months). Thir-
ty-seven (9%) and 22 patients (6%), re-
spectively, underwent coronary artery
bypass procedures and percutaneous
transluminal coronary angioplasty during
follow-up. Among the 144 patients who
had ischemia by DSE, 54 underwent sub-
sequent revascularization (91% of the to-
tal population revascularized). The
remaining 90 patients with ischemia were
treated medically during follow-up.
Clinical and DSE variables associated
with an increased risk of hard cardiac
events and all causes of mortality in the
univariate analysis are demonstrated in
Table 2.
Predictors of hard cardiac events and
total mortality in the multivariate analysis
model are presented in Table 3. Event-
free survival curves according to the re-
sults of DSE are presented in Fig. 1 for
hard cardiac events. Both fixed and tran-
sient wall motion abnormalities (isch-
emia) were associated with higher event
rate. The cumulative hard cardiac event
rate was higher in patients with abnormal,
as compared with patients with normal,
DSE results (7 vs. 5% at 1 year, 18 vs. 8%
at 3 years, and 23 vs. 10% at 5 years;
overall P 0.01). Survival curves accord-
ing to the presence of wall motion abnor-
malities at rest or induced during
dobutamine stress are shown in Fig. 2.
The cumulative death rate in patients with
abnormal, as compared with patients
with normal, DSE results was 9 vs. 3% at
1 year, 29 vs. 11% at 3 years, and 31 vs.
24% at 5 years (overall P  0.04).
CONCLUSIONS — In this study, we
assessed the predictors of death and non-
fatal myocardial infarction in 396 diabetic
patients with limited exercise capacity
and known or suspected CAD who un-
derwent DSE. During a median follow-up
period of 3 years, 97 patients died (55
cardiac deaths). Nonfatal myocardial in-
farction occurred in 27 patients. Clinical
predictors of hard cardiac events were a
history of congestive heart failure, previ-
ous myocardial infarction, hypercholes-
terolemia, and ejection fraction at rest.
Clinical predictors of all causes of mortal-
ity were age, hypercholesterolemia, ejec-
tion fraction at rest, and history of
congestive heart failure. DSE provided in-
cremental prognostic information for the
prediction of both end points. Hard car-
diac events were independently predicted
by ejection fraction at rest as well as by the
percentage of ischemic segments at stress.
These findings demonstrate the impor-
tance of resting LV function and the
severity of myocardial ischemia in deter-
mining the outcome of diabetic patients.
Peak dobutamine wall motion score
index, which measures the sum of resting
and stress-induced wall motion abnor-
malities, was incremental to clinical data
in the prediction of all causes of mortality.
The cumulative death rate in patients with
abnormal, as compared with patients
with normal, DSE results was 9 vs. 3% at
1 year, 29 vs. 11% at 3 years, and 31 vs.
Table 2—Univariate association of clinical and stress echocardiographic variables with risk of
hard cardiac events and death
Variables
Hard cardiac events Death
HR 95% CI P 2 HR 95% CI P 2
Age — — — — 1.03 1.01–1.05 0.003 9
Previous MI 2.1 1.2–3.4 0.004 8 — — — —
History heart
failure
2.3 1.4–3.7 0.0004 13 2.7 1.7–4.1 0.0001 21
WMSI rest 2.5 1.6–4.0 0.0001 18 2.3 1.5–3.4 0.0001 15
Ejection fraction
rest (%)
0.02 0.01–0.09 0.0001 25 0.05 0.01–0.2 0.0001 20
Rest WMA 0.91 0.88–0.95 0.0001 21 0.89 0.84–0.94 0.0001 16
WMSI peak — — — — 2.4 1.6–3.7 0.0001 18
Ischemic
segments (%)*
1.1 1.02–1.22 0.02 4 1.1 1.01–1.2 0.03 4
*Per increase of 10%. HR, hazard ratio; MI, myocardial infarction; WMA, wall motion abnormalities; WMSI,
wall motion score index.
Table 3—Independent predictors of hard cardiac events and death using a two-step model
Model Variables
Hard cardiac events Death
2 P HR (95% CI)
Model
2 2 P HR (95% CI)
Model
2
Clinical Age — — — 10 0.001 1.04 (1.01–1.06)
Heart failure 8 0.004 2.1 (1.3–3.3) 20 0.0001 2.8 (1.8–4.4)
Previous MI 6 0.01 1.9 (1.1–3.1) 18 — — — 43
Hypercholesterolemia 10 0.0009 2.7 (2.0–6.0) 4 0.04 1.6 (1.0–2.5)
Ejection fraction 8 0.004 0.017 (0.01–0.1) 8 0.004 0.1 (0.02–0.5)
Clinical 	
DSE Sex 5 0.03 0.5 (0.3–0.9) — — —
Heart failure 11 0.001 1.8 (1.1–2.9) — — —
Ejection fraction 19 0.0001 0.21 (0.01–0.12) — — — 52
Ischemic segments (%)* 3 0.07 1.1 (1.00–1.22) 37 — — —
WMSI peak — — — 13 0.0004 1.9 (1.36–2.65)
*Per increase of 10%. HR, hazard ratio; MI, myocardial infarction; WMSI, wall motion score index.
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24% at 5 years (overall P  0.04). From
these data it appears that the maximal
value of a normal DSE study in the pre-
diction of a lower risk status is obtained at
an intermediate term follow-up of 3 years,
when survival curves showed the greatest
diversion between patients with normal
and abnormal study.
Previous studies
To date, this is the first study that evalu-
ates the role of stress echocardiography in
the prediction of all causes of mortality in
diabetic patients. The prognostic value of
DSE in diabetic patients has been a sub-
ject of controversy among previous stud-
ies. Hung et al. (21) studied 116 diabetic
and 222 nondiabetic patients after acute
myocardial infarction. They observed that
shorter dobutamine time, as opposed to
DSE positivity, has a higher value for the
prediction of events in diabetic patients
during a mean follow-up of 21 months.
Conversely, Bates et al. (16) reported that
DSE was a powerful test for the prognostic
stratification of 53 patients with juvenile-
onset insulin-dependent diabetes who
were considered for kidney and/or pan-
creas transplantation. Recently, Bigi et al.
(22) studied 108 diabetic patients who
were followed-up for 20  17 months
after DSE and 151 diabetic patients who
were followed-up for 33  26 months
after dipyridamole stress test. Cox’s
model selected peak wall motion score in-
dex as the only significant independent
predictor of cardiac events. The study in-
cluded patients who were able to perform
exercise stress test and, as such, represent
a lower risk population. This may explain
the higher mortality rate in our study as
compared with Bigi et al. (24 vs. 8%). An-
other explanation for the higher mortality
in our study is the longer duration of the
follow-up (3 vs. 2 years). Elhendy et al.
(10) assessed the value of exercise echo-
cardiography in the prediction of cardiac
events in 563 diabetic patients. The extent
of both resting LV dysfunction and myo-
cardial ischemia was predictive of cardiac
events incremental to clinical data. The
event rate in that study was much lower
than in our study (9 vs. 21%), reflecting
the high-risk status of a population un-
able to perform exercise stress test in our
study. Although exercise stress testing is
the most physiological stress method for
inducing myocardial ischemia and pro-
vides data on exercise capacity, our study
showed that DSE is an alternative in pa-
tients with limited exercise capacity. Due
to the high event rate in this group, stress
testing is more likely to identify a larger
proportion of patients at highest risk of
adverse outcome.
The American Heart Association
recommended the use of exercise stress
myocardial perfusion imaging for the
evaluation of CAD in diabetic patients
based on the published data on the utility
of the technique in diabetic patients. It
was concluded that there are currently no
outcome data to define the role of stress
echocardiography as a prognostic tool in
diabetic patients (2). Our study supports
recent evidence of the value of stress
echocardiography as a prognostic tool in
diabetic patients (23,24).
Limitations of the study
While the results in this study support the
utility of DSE in patients with diabetes,
they do not demonstrate superiority of
DSE over exercise stress testing. The latter
provides additional prognostic informa-
tion by assessing exercise capacity, heart
rate recovery, and other parameters mea-
sured during treadmill or bike testing.
In conclusion, DSE provides data in-
cremental to clinical variables for the pre-
diction of death and cardiac events in
diabetic patients with suspected or
known CAD who are unable to perform
an adequate exercise stress test. Resting
LV function and extent of myocardial
ischemia during DSE are important pre-
dictors of outcome in these patients.
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